8-K: Veru Sells FC2 Female Condom Business for $18 Million, Shifts Focus to Biopharmaceuticals

Veru Inc. has divested its FC2 female condom business for $18 million to concentrate on its late-stage clinical drug pipeline.

Summary

• Veru Inc. has sold its FC2 female condom business to Clear Future, Inc. for $18 million in cash, subject to adjustments.
• The deal includes the transfer of Veru's UK and Malaysian subsidiaries related to the FC2 business.
• After accounting for a change of control payment to SWK Funding LLC and other transaction fees, Veru expects net proceeds of approximately $12.5 million.
• The sale allows Veru to focus on its biopharmaceutical pipeline, particularly its Phase 2b clinical trial for enobosarm.
• Veru's headcount will be reduced by approximately 90%, from 210 to 22, as a result of the sale.
• The company anticipates topline results from the enobosarm Phase 2b trial in January 2025.
• The Royalty Agreement with SWK Funding LLC will be terminated upon payment of the change of control premium, extinguishing $9.9 million in liabilities.

Sentiment

Score: 7

Explanation: The document is generally positive, highlighting the strategic shift and potential for growth in the biopharmaceutical sector. However, the significant headcount reduction and the need for future funding temper the overall optimism.

Positives

• The sale provides Veru with approximately $12.5 million in non-dilutive capital.
• The company can now focus its resources on its late-stage biopharmaceutical pipeline.
• The termination of the Royalty Agreement eliminates $9.9 million in liabilities.
• The company is expecting topline results from the enobosarm Phase 2b trial in January 2025.

Negatives

• Veru's headcount will be significantly reduced by approximately 90%.
• The company will no longer have revenue from the FC2 business.

Risks

• The actual proceeds from the sale may be subject to post-closing adjustments.
• The success of the enobosarm clinical trial is not guaranteed.
• The company may face challenges in transitioning to a pure biopharmaceutical company.
• The company may need to raise additional capital to fund its operations and clinical trials.

Future Outlook

Veru will focus on its biopharmaceutical pipeline, particularly the development of enobosarm for cardiometabolic diseases and oncology. The company expects topline results from the enobosarm Phase 2b trial in January 2025 and from the extension study in Q2 2025. The company will not undertake further development of sabizabulin for the treatment of viral-induced ARDS until it obtains funding from government grants, pharmaceutical company partnerships, or other similar third-party external sources.

Management Comments

• Mitchell Steiner, M.D., Chairman, President, and Chief Executive Officer of Veru Inc., stated that the monetization of the FC2 business allows Veru to be a pure biopharmaceutical company.
• He also expressed excitement about the company's strategic evolution to the treatment of cardiometabolic diseases.

Industry Context

The sale of the FC2 business reflects a strategic shift for Veru towards becoming a pure biopharmaceutical company. This move is in line with the trend of pharmaceutical companies focusing on core therapeutic areas and divesting non-core assets. The company's focus on enobosarm for sarcopenic obesity also aligns with the growing interest in treatments for age-related muscle loss and metabolic disorders.

Comparison to Industry Standards

• The divestiture of the FC2 business is similar to other pharmaceutical companies streamlining their operations to focus on core drug development programs.
• The focus on enobosarm for sarcopenic obesity is a novel approach, as most weight loss drugs do not specifically address muscle preservation.
• The company's Phase 2b trial for enobosarm is comparable to other clinical trials in the obesity and metabolic disease space, but with a unique focus on muscle mass.
• The reduction in headcount is a common practice after a divestiture, as the company adjusts its operations to the new business model.

Stakeholder Impact

• Shareholders will see a shift in the company's focus and potential for growth in the biopharmaceutical sector.
• Employees will experience a significant reduction in headcount.
• Customers of the FC2 business will now be served by Clear Future, Inc.
• Creditors will see the extinguishment of $9.9 million in liabilities related to the Royalty Agreement.

Next Steps

• Veru will focus on the execution and development of its late-stage clinical drug pipeline.
• The company will continue the Phase 2b QUALITY clinical trial evaluating enobosarm.
• Veru will prepare for the Phase 2b extension clinical trial to evaluate enobosarm's ability to maintain muscle and prevent fat gain after discontinuing a GLP-1 RA.
• The company will seek funding from government grants, pharmaceutical company partnerships, or other similar third-party external sources for the development of sabizabulin.

Key Dates

Keywords

FC2 female condom, Veru Inc, biopharmaceutical, enobosarm, clinical trial, sarcopenic obesity, weight loss, muscle preservation, Riva Ridge Capital Management, asset sale